Park B K, Choonara I A, Haynes B P, Breckenridge A M, Malia R G, Preston F E
Br J Clin Pharmacol. 1986 Mar;21(3):289-93. doi: 10.1111/j.1365-2125.1986.tb05192.x.
The case histories of two patients exposed to the novel anticoagulants brodifacoum and difenacoum are reported. Abnormal vitamin K1 metabolism, as indicated by elevated vitamin K1 2,3-epoxide plasma concentrations after i.v. administration of vitamin K1, could be detected for more than 18 months after exposure to the anticoagulants. There was a marked prolongation of prothrombin time (greater than 50 s) in both cases, at the time of exposure. However, subsequent haematological investigations (prothrombin time and vitamin K-dependent clotting factor activity) have been shown to be normal in both cases for at least 18 months. These cases confirm the long-acting nature of brodifacoum and difenacoum and present an apparent dissociation between the effect of coumarin anticoagulants on vitamin K1 metabolism and clotting factor activity.
报告了两名接触新型抗凝剂溴敌隆和敌鼠钠的患者的病历。静脉注射维生素K1后,血浆维生素K1 2,3-环氧化物浓度升高,表明维生素K1代谢异常,在接触抗凝剂后18个月以上仍可检测到。接触时,两例患者的凝血酶原时间均显著延长(大于50秒)。然而,随后的血液学检查(凝血酶原时间和维生素K依赖凝血因子活性)显示,两例患者至少18个月来均正常。这些病例证实了溴敌隆和敌鼠钠的长效性质,并显示了香豆素类抗凝剂对维生素K1代谢和凝血因子活性的影响之间存在明显的分离。